ERBB2 and non-small cell lung carcinoma: The trial involved 91 patients with advanced HER2+ NSCLC, who received RP2D at 6.4mg/kg every three weeks and not respond to previous treatments, which included 42 patients with HER2 mutant and 49 patients with HER2 overexpression.